Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).

Author:

Jones Jeffrey Alan1,Robak Tadeusz2,Wach Malgorzata3,Brown Jennifer R.4,Menter Alexander R.5,Vandenberghe Elizabeth6,Ysebaert Loic7,Wagner-Johnston Nina D.8,Polikoff Jonathan9,Awan Farrukh Tauseef1,Badoux Xavier Camille Albert10,Coutre Steven11,Spurgeon Stephen Edward Forbes12,Loscertales Javier13,Dreiling Lyndah14,Xing Guan14,Peterman Sissy14,Dubowy Ronald L.14,Flinn Ian15,Owen Carolyn16

Affiliation:

1. The Ohio State University Comprehensive Cancer Center, Columbus, OH;

2. Medical University of Lodz, Lodz, Poland;

3. Medical University of Lublin, Lublin, Poland;

4. Dana-Farber Cancer Institute, Boston, MA;

5. Kaiser Permanente Medical Group, Denver, CO;

6. Saint James's Hospital, Dublin, Ireland;

7. CHU Toulouse, Toulouse, France;

8. The Johns Hopkins Hospital, Baltimore, MD;

9. Kaiser Hospital San Diego, San Marcos, CA;

10. St George Hospital, Cammeray, Australia;

11. Stanford University, Stanford, CA;

12. Oregon Health and Science University, Portland, OR;

13. Hospital Universitario La Princesa, Madrid, Spain;

14. Gilead Sciences, Inc., Foster City, CA;

15. Hematologic Malignancies Research Program, Sarah Cannon Research Institute, Nashville, TN;

16. Alberta Health Services, Calgary, AB, Canada;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3